Johnson & Johnson (NYSE:JNJ) Shares Sold by Peoples Financial Services CORP.

Peoples Financial Services CORP. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,123 shares of the company’s stock after selling 385 shares during the quarter. Johnson & Johnson comprises 1.9% of Peoples Financial Services CORP.’s investment portfolio, making the stock its 11th biggest holding. Peoples Financial Services CORP.’s holdings in Johnson & Johnson were worth $4,158,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. MTM Investment Management LLC raised its stake in Johnson & Johnson by 0.5% during the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock valued at $1,749,000 after purchasing an additional 61 shares during the period. OneAscent Financial Services LLC raised its position in Johnson & Johnson by 3.3% during the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock valued at $308,000 after buying an additional 63 shares during the period. Beech Hill Advisors Inc. lifted its stake in Johnson & Johnson by 0.3% in the 2nd quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock worth $3,906,000 after acquiring an additional 63 shares in the last quarter. FIDELIS iM LLC boosted its position in Johnson & Johnson by 3.1% during the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after acquiring an additional 64 shares during the period. Finally, Well Done LLC grew its stake in Johnson & Johnson by 0.4% during the 1st quarter. Well Done LLC now owns 15,584 shares of the company’s stock valued at $2,415,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Barclays lowered their price target on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a report on Friday, September 8th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 8th. Finally, JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $170.65.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $162.41 on Tuesday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The firm has a fifty day simple moving average of $166.21 and a 200-day simple moving average of $161.83. The stock has a market capitalization of $422.10 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 3.26 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.59 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.03 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.